186 related articles for article (PubMed ID: 36504457)
21. Diffuse-type tenosynovial giant cell tumor with t(1;17)(p13;p13) and trisomy 5.
Nishio J; Kamachi Y; Iwasaki H; Naito M
In Vivo; 2014; 28(5):949-52. PubMed ID: 25189912
[TBL] [Abstract][Full Text] [Related]
22. Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-
Vougiouklakis T; Shen G; Feng X; Hoda ST; Jour G
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906059
[TBL] [Abstract][Full Text] [Related]
23. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors.
van IJzendoorn DGP; Matusiak M; Charville GW; Spierenburg G; Varma S; Colburg DRC; van de Sande MAJ; van Langevelde K; Mohler DG; Ganjoo KN; Bui NQ; Avedian RS; Bovée JVMG; Steffner R; West RB; van de Rijn M
Clin Cancer Res; 2022 Nov; 28(22):4934-4946. PubMed ID: 36007098
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
[TBL] [Abstract][Full Text] [Related]
25. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
[TBL] [Abstract][Full Text] [Related]
26. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
[TBL] [Abstract][Full Text] [Related]
27. Giant Cell Tumor of Tendon Sheath With a t(1;1)(p13;p34) Chromosomal Translocation.
Nakayama S; Nishio J; Nakatani K; Nabeshima K; Yamamoto T
Anticancer Res; 2020 Aug; 40(8):4373-4377. PubMed ID: 32727765
[TBL] [Abstract][Full Text] [Related]
28. Clinical and morphological correlations and histopathology of joint damage in patients with diffuse-type tenosynovial giant cell tumor.
Dyadyk OO; Hryhorovska AV
Wiad Lek; 2019; 72(12 cz 1):2269-2276. PubMed ID: 32124739
[TBL] [Abstract][Full Text] [Related]
29. The macrophage colony-stimulating factor 1 response signature in breast carcinoma.
Beck AH; Espinosa I; Edris B; Li R; Montgomery K; Zhu S; Varma S; Marinelli RJ; van de Rijn M; West RB
Clin Cancer Res; 2009 Feb; 15(3):778-87. PubMed ID: 19188147
[TBL] [Abstract][Full Text] [Related]
30. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
31. Molecular cytogenetic characterization of tenosynovial giant cell tumors.
Brandal P; Bjerkehagen B; Heim S
Neoplasia; 2004; 6(5):578-83. PubMed ID: 15548367
[TBL] [Abstract][Full Text] [Related]
32. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.
Helming A; Hansford B; Beckett B
Skeletal Radiol; 2022 May; 51(5):1085-1091. PubMed ID: 34586485
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.
Cheng H; Clarkson PW; Gao D; Pacheco M; Wang Y; Nielsen TO
Sarcoma; 2010; 2010():174528. PubMed ID: 20981142
[TBL] [Abstract][Full Text] [Related]
34. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors.
Nilsson M; Höglund M; Panagopoulos I; Sciot R; Dal Cin P; Debiec-Rychter M; Mertens F; Mandahl N
Virchows Arch; 2002 Nov; 441(5):475-80. PubMed ID: 12447678
[TBL] [Abstract][Full Text] [Related]
35. Tenosynovial giant cell tumor.
Kager M; Kager R; Fałek P; Fałek A; Szczypiór G; Niemunis-Sawicka J; Rzepecka-Wejs L; Starosławska E; Burdan F
Folia Med Cracov; 2022; 62(2):93-107. PubMed ID: 36256897
[TBL] [Abstract][Full Text] [Related]
36. Tenosynovial giant cell tumour (pigmented villonodular synovitis-)-like changes in periprosthetic interface membranes.
Söder S; Sesselmann S; Aigner T; Oehler S; Agaimy A
Virchows Arch; 2016 Feb; 468(2):231-8. PubMed ID: 26553457
[TBL] [Abstract][Full Text] [Related]
37. Diffuse-Type Tenosynovial Giant Cell Tumor: What Are the Important Findings on the Initial and Follow-Up MRI?
Choi WS; Lee SK; Kim JY; Kim Y
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254890
[TBL] [Abstract][Full Text] [Related]
38. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
39. Prediction of local recurrence in tenosynovial giant cell tumor of the knee: Based on preoperative MRI evaluation into disease subtypes and severity.
Kim JH; Lee SK; Kim JY
PLoS One; 2023; 18(6):e0287028. PubMed ID: 37315053
[TBL] [Abstract][Full Text] [Related]
40. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
